DE602005014778D1 - Timp-2 als ziel/marker des versagens von beta-zellen - Google Patents

Timp-2 als ziel/marker des versagens von beta-zellen

Info

Publication number
DE602005014778D1
DE602005014778D1 DE602005014778T DE602005014778T DE602005014778D1 DE 602005014778 D1 DE602005014778 D1 DE 602005014778D1 DE 602005014778 T DE602005014778 T DE 602005014778T DE 602005014778 T DE602005014778 T DE 602005014778T DE 602005014778 D1 DE602005014778 D1 DE 602005014778D1
Authority
DE
Germany
Prior art keywords
timp
failing
marker
target
beta cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005014778T
Other languages
English (en)
Inventor
Andreas Christ
Stefan Evers
Kurt Krapfenbauer
Elena Sebokova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602005014778D1 publication Critical patent/DE602005014778D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE602005014778T 2004-07-28 2005-07-19 Timp-2 als ziel/marker des versagens von beta-zellen Active DE602005014778D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103608 2004-07-28
PCT/EP2005/007853 WO2006010529A1 (en) 2004-07-28 2005-07-19 Timp-2 as target/marker of beta cell failure

Publications (1)

Publication Number Publication Date
DE602005014778D1 true DE602005014778D1 (de) 2009-07-16

Family

ID=34972635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005014778T Active DE602005014778D1 (de) 2004-07-28 2005-07-19 Timp-2 als ziel/marker des versagens von beta-zellen

Country Status (9)

Country Link
US (1) US20100009462A1 (de)
EP (1) EP1774338B1 (de)
JP (1) JP4562771B2 (de)
CN (1) CN1993619A (de)
AT (1) ATE433115T1 (de)
CA (1) CA2574417C (de)
DE (1) DE602005014778D1 (de)
ES (1) ES2325789T3 (de)
WO (1) WO2006010529A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102003258B1 (ko) 2009-12-20 2019-07-24 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
ES2734494T3 (es) 2011-12-08 2019-12-10 Astute Medical Inc Métodos y usos para el diagnóstico de una lesión renal y de una insuficiencia renal
CN107976547B (zh) 2013-01-17 2020-08-25 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
WO2015021308A1 (en) * 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
WO2015084939A1 (en) 2013-12-03 2015-06-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN109844526A (zh) 2016-06-06 2019-06-04 机敏医药股份有限公司 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤
US10224053B2 (en) * 2017-03-24 2019-03-05 Hyundai Motor Company Audio signal quality enhancement based on quantitative SNR analysis and adaptive Wiener filtering
EP3606554A4 (de) * 2017-04-05 2020-12-09 Astute Medical, Inc. Tests auf timp2 mit verbesserter leistung bei biologischen proben

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181939B1 (de) * 1999-05-24 2006-05-31 Shionogi & Co., Ltd. Methode zum auswerten der in vivo matrix-metalloproteinasen hemmenden aktivität
US6673623B1 (en) * 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
AUPS282002A0 (en) * 2002-06-06 2002-06-27 Gropep Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
JP4562771B2 (ja) 2010-10-13
ATE433115T1 (de) 2009-06-15
US20100009462A1 (en) 2010-01-14
WO2006010529A1 (en) 2006-02-02
JP2008508502A (ja) 2008-03-21
EP1774338B1 (de) 2009-06-03
CA2574417C (en) 2010-09-28
ES2325789T3 (es) 2009-09-17
EP1774338A1 (de) 2007-04-18
CA2574417A1 (en) 2006-02-02
CN1993619A (zh) 2007-07-04

Similar Documents

Publication Publication Date Title
ATE528300T1 (de) Bizyklische verbindungen und ihre verwendung als antidiabetika
WO2006084195A3 (en) Personal assessment including familial risk analysis for personalized disease prevention plan
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
DE602007008224D1 (de) Vorhersage von letalität und detektion von schweren erkrankungen
WO2006133287A3 (en) Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
EP1547996A4 (de) Diagnostische sonden und heilmittel für krankheiten, bei denen prionprotein akkumuliert wird, und anfürbereagenzien für prionprotein
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
MX2010014228A (es) Metodos y productos de diagnostico del p/gf-1 acompañante.
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
ATE537445T1 (de) Screening-verfahren
DE602005014778D1 (de) Timp-2 als ziel/marker des versagens von beta-zellen
ATE427489T1 (de) Diagnostische marker fur ischamie und mortalitatsrisiken
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2008060400A3 (en) Sirtuin polymorphisms and methods of use thereof
AU2006228990A8 (en) A method of diagnosis and treatment and agents useful for same
MX339765B (es) Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
WO2009029587A3 (en) Compositions and methods for diagnosing and treating macular degeneration
DE602005010712D1 (de) Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung
WO2006010533A3 (en) Pancreatic polypeptide as target/marker of beta cell failure
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
WO2006119888A3 (en) Butyrylcholinesterase as target/marker for insulin resistance
WO2010121834A3 (en) Irak kinase family as novel target and biomarker for alzheimer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition